DoH to consider use of Avastin for wet AMD

Appraisal of the intravitreal use of the anti-VEGF drug bevacizumab (Avastin) is being considered by the Department of Health (DoH) after recommendation from the National Institute for Health and Clinical Excellence (NICE).

However, the Royal National Institute of Blind People (RNIB) has voiced concerns about the potential impact of a decision to appraise Avastin on the regulatory system.

Support for the evaluation was the main conclusion of a report published by NICE in December on the feasibility of the use of Avastin to treat eye conditions after having been asked to consider the issue by the DoH.

NICE undertook a consultation exercise, based on a briefing paper, attended by 26 representatives from patient groups, NHS organisations, professional groups, pharmaceutical companies and the DoH.